Sandbox:Rina Ghorpade: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(11 intermediate revisions by the same user not shown)
Line 1: Line 1:
"[[User:Rina Ghorpade|Rina Ghorpade,MD]][mailto:rina.ghorpade@gmail.com]"
Advanced heart failure.
Redirect [[MI]]
<references />Majority of cases of HGA are transmitted by two different ticks in the USA.
Life cycle of I. scapularis and I. pacificus.


An adult female lay eggs in cluteches of approximate 1500-3000 eggs in spring, from egges six-legged larvae emerge. Larvae usually feed on rodent/bird blood and get infected by rickettsial parasaties usually in summer. Larvae transformed into eight legged structure calle Nymph, nymphs lie dormant in fall/winter, nymphs start feeding on deer, humans, and dogs in the next spring. Nymphs then molt into adults which aslo has eight legs, and adults find third host, these adults mate on or off a host, and once engorged and met, female adult tick a thousands of eggs in clutch before dying.
==Differentiating SWS from other neuro-cutaneous syndromes==


<br />
 
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
[Differential dx1]
[Differential dx2]
[Differential dx3]
 
Epidemiology and Demographics
The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
Age
Patients of all age groups may develop [disease name].
[Disease name] is more commonly observed among patients aged [age range] years old.
[Disease name] is more commonly observed among [elderly patients/young patients/children].
Gender
[Disease name] affects men and women equally.
[Gender 1] are more commonly affected with [disease name] than [gender 2].
The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
Race
There is no racial predilection for [disease name].
[Disease name] usually affects individuals of the [race 1] race.
[Race 2] individuals are less likely to develop [disease name].
 
 
Risk Factors
Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
 
 
Natural History, Complications and Prognosis
 
 
The majority of patients with [disease name] remain asymptomatic for [duration/years].
Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].
 
 
Diagnosis
Diagnostic Criteria
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
[criterion 1]
[criterion 2]
[criterion 3]
[criterion 4]
Symptoms
[Disease name] is usually asymptomatic.
Symptoms of [disease name] may include the following:
[symptom 1]
[symptom 2]
[symptom 3]
[symptom 4]
[symptom 5]
[symptom 6]
 
 
Physical Examination
Patients with [disease name] usually appear [general appearance].
Physical examination may be remarkable for:
[finding 1]
[finding 2]
[finding 3]
[finding 4]
[finding 5]
[finding 6]
 
Laboratory Findings
There are no specific laboratory findings associated with [disease name].
A [positive/negative] [test name] is diagnostic of [disease name].
An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
 
 
Imaging Findings
There are no [imaging study] findings associated with [disease name].
[Imaging study 1] is the imaging modality of choice for [disease name].
On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
[Disease name] may also be diagnosed using [diagnostic study name].
Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
 
 
 
Treatment
Medical Therapy
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
[Medical therapy 1] acts by [mechanism of action 1].
Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
Surgery is the mainstay of therapy for [disease name].
[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
[Surgical procedure] can only be performed for patients with [disease stage] [disease name].
 
 
Prevention
 
 
There are no primary preventive measures available for [disease name].
Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

Latest revision as of 23:44, 12 June 2020

Differentiating SWS from other neuro-cutaneous syndromes

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as: [Differential dx1] [Differential dx2] [Differential dx3]

Epidemiology and Demographics The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide. In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location]. Age Patients of all age groups may develop [disease name]. [Disease name] is more commonly observed among patients aged [age range] years old. [Disease name] is more commonly observed among [elderly patients/young patients/children]. Gender [Disease name] affects men and women equally. [Gender 1] are more commonly affected with [disease name] than [gender 2]. The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1. Race There is no racial predilection for [disease name]. [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].


Risk Factors Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].


Natural History, Complications and Prognosis


The majority of patients with [disease name] remain asymptomatic for [duration/years]. Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3]. If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. Common complications of [disease name] include [complication 1], [complication 2], and [complication 3]. Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].


Diagnosis Diagnostic Criteria The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1] [criterion 2] [criterion 3] [criterion 4] Symptoms [Disease name] is usually asymptomatic. Symptoms of [disease name] may include the following: [symptom 1] [symptom 2] [symptom 3] [symptom 4] [symptom 5] [symptom 6]


Physical Examination Patients with [disease name] usually appear [general appearance]. Physical examination may be remarkable for: [finding 1] [finding 2] [finding 3] [finding 4] [finding 5] [finding 6]

Laboratory Findings There are no specific laboratory findings associated with [disease name]. A [positive/negative] [test name] is diagnostic of [disease name]. An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name]. Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].


Imaging Findings There are no [imaging study] findings associated with [disease name]. [Imaging study 1] is the imaging modality of choice for [disease name]. On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3]. [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3]. Other Diagnostic Studies [Disease name] may also be diagnosed using [diagnostic study name]. Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].


Treatment Medical Therapy There is no treatment for [disease name]; the mainstay of therapy is supportive care. The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2]. [Medical therapy 1] acts by [mechanism of action 1]. Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration]. Surgery Surgery is the mainstay of therapy for [disease name]. [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name]. [Surgical procedure] can only be performed for patients with [disease stage] [disease name].


Prevention


There are no primary preventive measures available for [disease name]. Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3]. Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].